{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:09:52Z","timestamp":1790453392989,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.bcmd.2011.09.007","type":"journal-article","created":{"date-parts":[[2011,10,31]],"date-time":"2011-10-31T03:13:33Z","timestamp":1320030813000},"page":"68-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines"],"prefix":"10.1016","volume":"48","author":[{"given":"Carlo","family":"Visco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Castegnaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Chieregato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Albiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Zanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Madeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rodeghiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2011.09.007_bb0005","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0010","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0015","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07124.x","article-title":"Advances in the understanding of mantle cell lymphoma","volume":"142","author":"Jares","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0025","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0030","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0035","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0040","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","article-title":"High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas","volume":"128","author":"Bremer","year":"2002","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0045","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0050","first-page":"1357","article-title":"Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I\/II study of the German CLL Study Group","volume":"90","author":"Bergmann","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0055","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0060","first-page":"1287","article-title":"The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy","volume":"90","author":"Knop","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0065","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1023\/A:1008309911008","article-title":"Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours","volume":"11","author":"Schoffski","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0070","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.JTO.0000263714.46449.4c","article-title":"Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer","volume":"2","author":"Koster","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2006.09.029","article-title":"Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients","volume":"55","author":"Schmittel","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0080","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/cncr.24057","article-title":"Bendamustine: a new look at an old drug","volume":"115","author":"Kalaycio","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0085","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood.V110.11.385.385","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas \u2014 first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)","volume":"110","author":"Rummel","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0090","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.V106.11.923.923","article-title":"Bendamustine HCl (TREANDA\u2122) treatment in combination with rituximab results in objective responses in patients with refractory\/relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma: results from phase II multicenter study (SDX-105-02)","volume":"106","author":"Robinson","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0095","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","article-title":"Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy","volume":"11","author":"Gandhi","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/1042819021000054670","article-title":"In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential","volume":"44","author":"Chow","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0105","first-page":"63","article-title":"In vitro modulation of ara-CTP accumulation in fresh AML cells by bendamustine in comparison with fludarabine, 2-CDA and gemcitabine [abstract]","volume":"94","author":"Staib","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0110","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/sonc.2002.34872","article-title":"Metabolism and mechanisms of action of bendamustine: rationales for combination therapies","volume":"29","author":"Gandhi","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/cyto.990050410","article-title":"7-amino-actinomycin D as a specific fluorophore for DNA content analysis by laser flow cytometry","volume":"5","author":"Zelenin","year":"1984","journal-title":"Cytometry"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0120","first-page":"9.26.1","article-title":"Immunophenotyping and DNA content analysis of acetone-fixed cells","volume":"46","author":"Mancaniello","year":"2008","journal-title":"Curr. Protoc. Cytom."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0125","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1083\/jcb.60.2.523","article-title":"Mathematical analysis of DNA distributions derived from flow microfluorometry","volume":"60","author":"Dean","year":"1974","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1006\/bbrc.1993.2438","article-title":"A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5\u2032,6,6\u2032-tetrachloro-1,1\u2032,3,3\u2032-tetraethylbenzimidazolcarbocyanine iodide (JC-1)","volume":"197","author":"Cossarizza","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0135","first-page":"2515","article-title":"Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production","volume":"51","author":"Vistica","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1387-2656(05)11004-7","article-title":"Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction","volume":"11","author":"Berridge","year":"2005","journal-title":"Biotechnol. Annu. Rev."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0145","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0165-6147(83)90490-X","article-title":"Analysis of combined drug effects: a new look at a very old problem","volume":"4","author":"Chou","year":"1983","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0150","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0155","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1273::AID-CNCR13>3.0.CO;2-4","article-title":"Cancer burden in the aged: an epidemiologic and demographic overview","volume":"80","author":"Yancik","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0160","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0165","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1182\/blood.V112.11.262.262","article-title":"Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results of an international study (NHL-003)","volume":"112","author":"Zinzani","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0170","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0175","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0180","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0185","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1200\/jco.2008.26.15_suppl.8513","article-title":"Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy","volume":"26","author":"Hess","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0190","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0195","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0200","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0205","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0210","first-page":"485","article-title":"In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine","volume":"86","author":"Chow","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0215","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/sj.leu.2402651","article-title":"In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia","volume":"16","author":"Schwanen","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2011.09.007_bb0220","first-page":"329","article-title":"Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells","volume":"48","author":"Gandhi","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0225","first-page":"897","article-title":"Fludarabine infusion potentiates Arabinosylcytosine lymphocytic leukemia metabolism in lymphocytes of patients with chronic lymphocytic leukemia","volume":"52","author":"Gandhi","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0230","first-page":"5037","article-title":"Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia","volume":"23","author":"Sutoh","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0235","first-page":"786","article-title":"Brief exposure to SDX-105 (Treanda\u2122) activates potent apoptosis and cell death in lymphoma and leukemia cells","volume":"46","author":"Bendall","year":"2005","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0240","first-page":"538","article-title":"Mitotic catastrophe induced in cells treated with SDX-105 (Treanda\u2122)","volume":"46","author":"Niemeyer","year":"2005","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bcmd.2011.09.007_bb0245","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1158\/1078-0432.CCR-08-0388","article-title":"Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling","volume":"14","author":"Rou\u00e9","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcmd.2011.09.007_bb0250","first-page":"162","article-title":"Rituximab, bendamustine and cytarabine (R-BAC) is a very active regimen in patients with mantle cell lymphoma not eligible for intensive chemotherapy or autologous transplant","volume":"22","author":"Visco","year":"2011","journal-title":"Ann. Oncol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979611001896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979611001896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:28:26Z","timestamp":1761049706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979611001896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1079979611001896"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2011.09.007","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2011.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}